Advanced MR Imaging in Dementia Flashcards

1
Q

What is Alzheimer’s pathology?

A
  1. Neuritic plaques - extracellular AB deposition + inflammatory cells
  2. Neurofibrillary tangles - insoluble tau protein inside neurons
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is multiple Micronleeds in AD relevance?

A
Defined as >8 MBs at 1.5T
• Compared to AD w/o MBs
– n=21 versus n=42
• Demographics similar
– same age
• MRI similar atrophy
– more WMH
• Worse cognition
• Lower CSF Abeta
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is congophylic amyloid angiopathy?

A

Some of the amyloid are deposited on the vessel walls by refringent material around the vessels and leads to thickening of the vessels and narrowing of the vessels which become fragile and microhaemorrhage can occur in the vessel wall which leads to susceptibility weighted defect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is cerebral amyloid angiopathy with inflammatory reaction?

A

Develop periods of inflammation spontaneously
Develop out blown of the venous and perivascular drainage and develop oedema and swelling
• Can become symptomatic – become drowsy and encephalitic
• May be responsive to steroid treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is molecular imaging for Dementia?

A
11C-PIB – amyloid deposition (PET)
– new 18F tracers licensed, not reimbursed
• flutematemol, florbetaben, florbetapir
– FDDNP less robust
• 123I-FP-CIT – dopaminergic receptor (SPECT)
– DAT-scan 123I-Ioflupane
• 18F-AV1451 – tau deposition (PET)
– others in development
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Fluorinated tracers?

A
  • Positive scan in AD
  • Negative scan in HC and FTD
  • See uptake in the white matter but not in the cortex
  • There is similar behaviour for a negative and positive scanner
  • Subtle differences between the tracers – some have stronger white matter binding in others
  • In the negative scan you see no uptake in the white matter and see the white matter ramification – in the positive scan it gets all blurred
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Amyloid PET in suspected AD:

A
  • With amyloid you cannot look at the original pattern
  • In positive scan amyloid is deposited all over the cortex while the atrophy/TAU uptake tends to be region specific either medial or parietal temporal
  • TAU and atrophy in MRI have similar distribution in a typical Alzheimer’s patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Combined amyloid and dopamine PET:

A
  • Tease out various groups
  • AD is amyloid positive with a normal dopamine scan
  • DLB is amyloid negative scan with a positive dopamine scan
  • FTD is both negative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PET tracers – TAU:

A
  • There is uptake in the medial temporal lobe and also parietal areas
  • In HC both tracers would be negative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is functional imaging in Dementia?

A

18F-FDG – glucose metabolism (PET)
• Tc-HMPAO – cerebral blood flow (SPECT)
• ASL – cerebral blood-flow (MRI)
• Rs-FMRI – resting-state connectivity (MRI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is 18F-FDG PET ?

A

this is a fluorinated tracer

  • It is a hot tracer, glucose-analogin
  • The brain uses a lot of glucose
  • You are looking at a hot background – making it slightly difficult to find the abnormality
  • Amyloid and Tau are cold tracers – normally there is no uptake in the brain – it is much easier to look for an abnormality
  • With FDG – you have to have a comparison to a normal data base or look for local differences
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

FDG-PET in AD – posterior cingulate:

A
  • On the left, normal FDG – all of the cortex is red
  • Looking for areas that have a reduced tracer uptake – occurs in the parietal, precuneus – it goes from parietal to temporal
  • Look for hypo-metabolism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is voxel-base mapping?

A

– have a series of normal PET scans and put subject in and produces a statistical map showing you were the subject deviates most from abnormality
• Red – the most abnormal
• Dark – the normal pattern – no difference compared to a reference of normal PET scans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

FDG and Amyloid PET – AD vs FTD:

A

• Clinical AD
- Amyloid scans were positive
- FDG was abnormal with a posterior hypometabolism
- Both are consistent with AD and pathology was AD
• Clinical FTLD-ALS
- Various mutations such as C9ORF and also others produce both FDG and MND
- Amyloid scan was negative
- FDG was abnormal with hypometabolism in the frontal lobe consistent with FTLD
• Clinical AD
- Amyloid scan is positive
- FDG is much like the FTLD case
- Pathology was Alzheimer’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

RS – fMRI: a new window to the brain:

A
  • Advantages – you do not need to inject anything contrary to PET
  • Look at brain activity – do either task or show some specific areas to light up as a function of the task e.g. map language for epilepsy surgery or study brain function in general
  • You study the brain at rest and look at various networks that are synchronised and drive the activity in the brain over time
  • You can do this with a run of approximately 5 minutes
  • Default-mode network (DMN) encompasses the precuneus – where atrophy occurs, where FDG shows hypometabolism
  • Encompasses area more anteriorly in the anterior cingulate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AD – decreased FC in the DMN:

A
  • DMN depicted in green – people with AD have a lower connectivity in this network
  • It is only on the group level – 50 subjects per group or so
  • On a single subject level – it is too noisy to be used as a clinical tool
  • If you look at people with APOE4 – normal healthy elderly and look at people with DMN – there is increased activity in the default mode network
17
Q

Resting state FMRI – rewiring in AD:

A
  • Look at all the connections in the brain and there are certain areas that are more connected than others
  • In AD, some connections are weaker than they were before with the dashed lines, but others are stronger
  • The dashed lines are the one connecting to the DMN – they get attenuated with disease
18
Q

Arterial spin labelling (ASL):

A
  • Non-invasive
  • Quantitative CBF
  • Short acquisition time
  • Standard MRI-scanner
19
Q

What are the hurdles in drug development in AD?

A

Target – is amyloid the culprit?
• Ineffective drugs
– different forms of amyloid (monomers, oligomers, fibrillary)
– novel targets (tau)
• Population (35% amyloid negative in BAPI studies)
– completed studies failed in mild/moderate AD
– ongoing studies in prodromal/preclinical patients/subjects
• Outcomes
– cognitive outcomes have learning effects
– surrogate endpoints (e.g. MRI and CSF) not validated

20
Q

What is MRI sequence for ARIA-E (Edema/Effusion)?

A

FLAIR

21
Q

What is MRI sequence for ARIA-H (Hemosiderin)?

A

T2*

22
Q

What is Parenchymal for ARIA-E (Edema/Effusion)?

A

Edema

23
Q

What is Parenchymal for ARIA-H(Hemosiderin)?

A

Microbleed

24
Q

What is sulcal for ARIA-E (Edema/Effusion)?

A

Effusion

25
Q

What is sulcal for ARIA-H (Hemosiderin)?

A

Siderosis

26
Q

What is the take home messages?

A

structural imaging

  • atrophy patterns late / non-specific
  • molecular imaging
  • amyloid tracers sensitive; low PPV
  • Tau tracers developing
  • missing: TDP, alpha-synuclein
  • functional imaging
  • may bridge the gap
  • FDG best validated
  • Therapy development & monitoring
  • select for secondary prevention
  • surrogate outcome measure